Sartorius BIA Separations and Arnav Biotech enter in collaboration to develop a mRNA synthesis and purification platform, supported with PATfix in-process analytical solution
Atlanta, Georgia and Ajdovscina, Slovenia, 2 February 2023
- Project combines Sartorius BIA Separations’ platforms for purification and analytics with Arnav’s innovative mRNA pipeline.
- The collaboration will leverage the companies’ track records in mRNA design, cost-efficient production and purification process and biological testing capabilities to develop a unique mRNA platform with low CoGs and high product purity
Sartorius BIA Separations (BIA), which is part of the international life science group Sartorius, and Arnav Biotech, an mRNA therapeutics and CDRMO developing mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities, are entering into a collaboration to develop a purification and analytical platform for the Arnav Biotech mRNA pipeline.
The new development will be based on the BIA chromatographic platform. Its PATfix™ analytical system will be used to optimize mRNA synthesis, purification, and quality control of Arnav’s therapeutics modalities. Together, Arnav Biotech and BIA plan to develop robust mRNA synthesis and purification processes to progress Arnav’s therapeutic pipeline to advanced clinical stages.
The objective of the project is to achieve the highest quality mRNA synthesis and purification process that is economic and adaptable across various therapeutic and vaccine platforms. This would enable Arnav to attain the highest mRNA yields with minimal non-ssRNA, DNA and other contaminants. This collaboration will promote an innovative approach with Cornerstone process development algorithm that will be applied to multiple mRNA designs.
The project will begin in April and reach development milestone by September 2023.
Sartorius BIA Separations is the leading developer of monolith technology and the exclusive producer of CIM® (Convective Interaction Media) chromatographic columns for the production, purification, and analysis of large biomolecules. The Company’s multi-use research, production, and training facility is headquartered in Ajdovščina, Slovenia, with sales and distribution offices located internationally.
Sartorius BIA Separations’ ongoing mission is to develop and produce CIM® monolithic columns of the highest quality and provide superior research and method development services for our customers. In addition, the Company now offers the highly versatile PATfix™ analytical system which enables analytical gradient separations.
Arnav Biotech is an US based mRNA therapeutics and CDRMO developing mRNA based broad-spectrum antivirals, mRNA-based vaccines, and other therapeutic modalities. Arnav is advancing its mRNA platform and process development to enhance the targeted expression of its diverse therapeutic candidates while unifying the synthesis and purification process. For more information, please contact us at email@example.com or visit www.arnavbiotech.com.